| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594511 | American Heart Journal | 2017 | 7 Pages |
Abstract
GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy-based strategy in subjects without need of chronic oral anticoagulation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Stephan MD, Jan PhD, Gennaro MD, Ana H.C. PhD, Roxana MD, Marco MD, PhD, Pascal MD, PhD, Robert C. MD, Usman MD, Gerrit-Anne PhD, Peter PhD, Albert A. PharmD BCPS, Ana MD, Karen MD, Melanie MD, George D. MD, PhD,